NeuroTrialNER: An Annotated Corpus for Neurological Diseases and Therapies in Clinical Trial Registries
Simona Doneva, Tilia Ellendorff, Beate Sick, Jean-Philippe Goldman, Amelia Cannon, Gerold Schneider, Benjamin Ineichen
摘要
Extracting and aggregating information from clinical trial registries could provide invaluable insights into the drug development landscape and advance the treatment of neurologic diseases. However, achieving this at scale is hampered by the volume of available data and the lack of an annotated corpus to assist in the development of automation tools. Thus, we introduce NeuroTrialNER, a new and fully open corpus for named entity recognition (NER). It comprises 1093 clinical trial summaries sourced from ClinicalTrials.gov, annotated for neurological diseases, therapeutic interventions, and control treatments. We describe our data collection process and the corpus in detail. We demonstrate its utility for NER using large language models and achieve a close-to-human performance. By bridging the gap in data resources, we hope to foster the development of text processing tools that help researchers navigate clinical trials data more easily.
问问这篇 Paper
智能体会读完全文。
Lune 把这篇 Paper 索引到了最后一个公式,引用它的顶会 Paper 也一样。你提问,回答直接引用原文。
它引用的顶会 Paper1
相关 Paper
- OpenNER 1.0: Standardized Open-Access Named Entity Recognition Datasets in 50+ LanguagesChester Palen-Michel, Maxwell Pickering, Maya Kruse, Jonne Sälevä 等EMNLP 2025 · 被引用 2 次
- COMETA: A Corpus for Medical Entity Linking in the Social MediaMarco Basaldella, Fangyu Liu, Ehsan Shareghi, Nigel CollierEMNLP 2020 · 被引用 4 次
- An Effective Transition-based Model for Discontinuous NERXiang Dai, Sarvnaz Karimi, Ben Hachey, Cécile ParisACL 2020 · 被引用 78 次
- CrossNER: Evaluating Cross-Domain Named Entity RecognitionZihan Liu, Yan Xu, Tiezheng Yu, Wenliang Dai 等AAAI 2021 · 被引用 201 次
- MS-Mentions: Consistently Annotating Entity Mentions in Materials Science Procedural TextTim O'Gorman, Zach Jensen, Sheshera Mysore, Kevin Huang 等EMNLP 2021 · 被引用 13 次
